Literature DB >> 27484159

Co-morbid conditions in use of recombinant tissue plasminogen activator (rt-PA) for the treatment of acute ischaemic stroke.

Thomas I Nathaniel1, Thomas Cochran1, Jose Chaves1, Eric Fulmer1, Crystal Sosa1, Sara Yi1, Megan Fredwall1, Shannon Sternberg2, Dawn Blackhurst2, Alfred Nelson2, Rodney Leacock2.   

Abstract

BACKGROUND: The objective of this study was to characterize the comorbidities in a population of patients with an acute ischaemic stroke, comparing patients that received recombinant tissue plasminogen activator (rt-PA) to those that did not receive rt-PA.
METHOD: In a retrospective sample of 663 patients admitted for acute ischaemic stroke, this study analysed the effects of co-morbid conditions in the use of rt-PA. It determined non-cerebrovascular risk factors (comorbidities) that differentiate patients who received rt-PA from those who did not receive rt-PA. RESULT: Patients with a history of carotid stenosis, CHF and previous strokes are significantly (p < 0.05) associated with high risk of not receiving rt-PA. A significant number of patients with a history of hypertension and smoking received rt-PA (p < 0.05).
CONCLUSION: The findings indicate that certain risk factors including carotid stenosis, CHF and previous stroke history impact the treatment of patients with acute ischaemic stroke, specifically the decision to administer rt-PA. Treatment with rt-PA is dependent on stroke severity and onset to treatment time, but the findings suggest that rt-PA use may also depend on patient comorbidities.

Entities:  

Keywords:  Comorbidity; hypertension; recombinant tissue plasminogen activator; stroke

Mesh:

Substances:

Year:  2016        PMID: 27484159     DOI: 10.1080/02699052.2016.1186840

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  13 in total

1.  Gender and thrombolysis therapy in acute ischemic stroke patients with incidence of obesity.

Authors:  Brice Blum; Alexandria Penwell; Leah Wormack; Brittany Walker; Shyyon Lari; Thomas I Nathaniel
Journal:  Neurol Sci       Date:  2019-05-02       Impact factor: 3.307

2.  Stroke Severity among Men and Women Acute Ischemic Stroke Patients in the Telestroke Network.

Authors:  Nicolas Poupore; Camron Edrissi; Mareshah Sowah; Madison Stanley; Jonah Joffe; Donovan Lewis; Teanda Cunningham; Carolyn Breauna Sanders; Krista Knisely; Chase Rathfoot; Thomas I Nathaniel
Journal:  Cerebrovasc Dis Extra       Date:  2022-06-08

3.  The Association Between an Antecedent of Transient Ischemic Attack Prior to Onset of Stroke and Functional Ambulatory Outcome.

Authors:  Nicolas Poupore; Dan Strat; Tristan Mackey; Thomas I Nathaniel
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

4.  Stroke and dyslipidemia: clinical risk factors in the telestroke versus non-telestroke.

Authors:  Jordan Gainey; Brice Blum; Bekah Bowie; Keiko Cooley; Lee Madeline; Ervin Lowther Ervin; Thomas I Nathaniel
Journal:  Lipids Health Dis       Date:  2018-09-27       Impact factor: 3.876

5.  The telestroke and thrombolysis therapy in diabetic stroke patients.

Authors:  Thomas I Nathaniel; Chibueze Ubah; Leah Wormack; Jordan Gainey
Journal:  Diabetol Metab Syndr       Date:  2019-05-09       Impact factor: 3.320

6.  Gender and thrombolysis therapy in stroke patients with incidence of dyslipidemia.

Authors:  Brice Blum; Leah Wormack; Mason Holtel; Alexandria Penwell; Shyyon Lari; Brittany Walker; Thomas I Nathaniel
Journal:  BMC Womens Health       Date:  2019-01-16       Impact factor: 2.809

7.  In acute ischemic stroke patients with smoking incidence, are more women than men more likely to be included or excluded from thrombolysis therapy?

Authors:  Oluyemi R Rotimi; Iretioluwa F Ajani; Alexandria Penwell; Shyyon Lari; Brittany Walker; Thomas I Nathaniel
Journal:  Womens Health (Lond)       Date:  2020 Jan-Dec

8.  Effect of antihypertensive medications on thrombolysis therapy and outcomes in acute ischemic stroke patients.

Authors:  Tyler Fleming; Brice Blum; Benjamin Averkamp; James Sullivan; Thomas Nathaniel
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-01-23       Impact factor: 3.738

9.  Investigation of Gender Differences and Exclusive Criteria in a Diabetic Acute Ischemic Stroke Population Treated with Recombinant Tissue-Type Plasminogen Activator (rtPA).

Authors:  Taylor Wapshott; Brice Blum; Williams Kelsey; Thomas I Nathaniel
Journal:  J Vasc Interv Neurol       Date:  2017-12

10.  Obstructive sleep apnea and stroke severity: Impact of clinical risk factors.

Authors:  Carolyn Breauna Sanders; Krista Knisely; Camron Edrissi; Chase Rathfoot; Nicolas Poupore; Leah Wormack; Thomas Nathaniel
Journal:  Brain Circ       Date:  2021-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.